Results 21 to 30 of about 2,000 (177)

Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. [PDF]

Clin Infect Dis
BACKGROUND People with HIV (PWH) with viremia despite oral antiretroviral therapy (ART) can achieve viral suppression (VS) using long-acting (LA)-ART. Scaling this approach has lagged, especially in highest HIV burden areas.
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF.   +15 more
europepmc   +2 more sources

Twice-Yearly Injectable Pre-Exposure Prophylaxis With Lenacapavir: Redefining Adherence and Access in the Global Fight Against HIV

Journal of the International Association of Providers of AIDS Care
Despite progress in human immunodeficiency virus (HIV) prevention, global targets remain unmet, with over 1.3 million new infections annually—driven by adherence challenges, stigma, and daily pill fatigue linked to oral pre-exposure prophylaxis (PrEP ...
Santosh Sah MBBS, Ureeba Iqbal MBBS, Trilok Mishra MBBS, Najeeb Ullah MBBS, Tularam Yadav MBBS   +4 more
doaj   +2 more sources

Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series. [PDF]

Clin Infect Dis
Background Some individuals with human immunodeficiency virus (HIV-1) have acquired multidrug-resistant (MDR) strains of HIV and/or are nonadherent to antiretroviral (ARV) medication.
Rolle C, Achhra A, Harbison C, Finkel D, Lucasti C, Martorell C, McClendon T, Slim J.   +7 more
europepmc   +2 more sources

Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2

Viruses
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase.
Irene Wanjiru Kiarie, Gyula Hoffka, Manon Laporte, Pieter Leyssen, Johan Neyts, József Tőzsér, Mohamed Mahdi   +6 more
doaj   +2 more sources

Practical Synthesis of 7-Bromo-4-chloro-1H-indazol-3-amine: An Important Intermediate to Lenacapavir

Molecules
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections.
Naeem Asad, Michael Lyons, Shirley Muniz Machado Rodrigues, Justina M. Burns, Thomas D. Roper, G. Michael Laidlaw, Saeed Ahmad, B. Frank Gupton, Douglas Klumpp, Limei Jin   +9 more
doaj   +2 more sources

Dollars and dilemmas: lenacapavir’s pricing, patents, and the path to affordability

International Journal for Equity in Health
Lenacapavir (Yeztugo), the world’s first twice-yearly human immunodeficiency virus (HIV) prevention injection, offers transformative potential but faces a critical challenge: affordability.
Victor Abiola Adepoju, Abdulrakib Abdulrahim   +1 more
doaj   +2 more sources

Global regulatory collaboration for the assessment of lenacapavir as a long-acting pre-exposure prophylaxis against HIV infection [PDF]

Frontiers in Public Health
Hendy Kristyanto, María Isabel González-Tomé, Viktor Vlcek, Filip Josephson, Patrick Vrijlandt, Patrick Vrijlandt, Nicholas Perombelon   +6 more
doaj   +2 more sources

Lenacapavir como profilaxis preexposición PrEP del Virus de la Inmunodeficiencia Humana [PDF]

Ciencia y Educación
A pesar de los avances en la prevención del VIH, las brechas en adherencia limitan la efectividad de la PrEP oral diaria, especialmente en poblaciones clave.
Diego Steven Guerrero Arroyo, Doris Vanesa Palacios Vargas   +1 more
doaj   +2 more sources

HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing

Viruses, 2023
Background: With the approval of the HIV-1 capsid inhibitor, lenacapavir, capsid sequencing will be required for managing lenacapavir-experienced individuals with detectable viremia.
Kaiming Tao, Soo-Yon Rhee, Philip L. Tzou, Zachary A. Osman, Sergei L. Kosakovsky Pond, Susan P. Holmes, Robert W. Shafer   +6 more
doaj   +1 more source

Lenacapavir’s success: Revitalizing antiviral drug discovery

Virulence
David Sanchez, Daniel Miranda
exaly   +3 more sources